Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPKAPK2 | P49137 | 2/20 | 0.47 |
| ▸ | TNKS | O95271 | 1/20 | 0.46 |
| ▸ | PARP1 | P09874 | 4/20 | 0.45 |
| ▸ | IDO1 | P14902 | 1/20 | 0.44 |
| ▸ | TDO2 | P48775 | 1/20 | 0.44 |
| ▸ | IDO2 | Q6ZQW0 | 1/20 | 0.44 |
| ▸ | KIT | P10721 | 2/20 | 0.44 |
| ▸ | HDAC3 | O15379 | 1/20 | 0.44 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | HDAC2 | Q92769 | 1/20 | 0.44 |
| ▸ | HDAC8 | Q9BY41 | 1/20 | 0.44 |
| ▸ | HDAC6 | Q9UBN7 | 1/20 | 0.44 |
| ▸ | MAPK8 | P45983 | 3/20 | 0.43 |
| ▸ | AURKA | O14965 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 1/20 | 0.43 |
| ▸ | LCK | P06239 | 1/20 | 0.43 |
| ▸ | MET | P08581 | 1/20 | 0.43 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.43 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | SYK | P43405 | 1/20 | 0.43 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL148677 | 0.83 | GSK3B (0.51) | TNKSPARP1IDO1TDO2IDO2 | |
| SCHEMBL30434521 | 0.83 | GSK3B (0.51) | TNKSPARP1IDO1TDO2IDO2 | |
| SCHEMBL1644051 | 0.82 | TNKS (0.54) | TNKSPARP1IDO1TDO2IDO2 | |
| SCHEMBL18643551 | 0.81 | PARP1 (0.54) | TNKSPARP1IDO1TDO2IDO2 | |
| SCHEMBL121941 | 0.81 | TNKS (0.44) | TNKSPARP1IDO1TDO2IDO2 | |
| SCHEMBL30434653 | 0.81 | TNKS (0.44) | TNKSPARP1IDO1TDO2IDO2 | |
| SCHEMBL377722 | 0.80 | HTR1A (0.46) | TNKSPARP1IDO1TDO2HDAC3 | |
| SCHEMBL378321 | 0.79 | TNKS (0.50) | TNKSPARP1IDO1TDO2IDO2 | |
| SCHEMBL21524687 | 0.76 | PARP1 (0.51) | MAPKAPK2TNKSPARP1IDO1TDO2 | |
| SCHEMBL27683290 | 0.75 | PARP1 (0.52) | TNKSPARP1IDO1TDO2IDO2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 23 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | claimed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | claimed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | claimed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | claimed |
| EP-2408454-B1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP (CA) | 2024-07-24 | — | — | EP | disclosed |
| US-11407719-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2022-08-09 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2021-03-11 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-10882828-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2021-01-05 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2019-04-25 | — | — | US | disclosed |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2016-05-19 | — | — | US | disclosed |
| US-9238640-B2 | Anti-inflammatory agents | RESVERLOGIX CORP. (CA) | 2016-01-19 | — | — | US | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | HEPALINK (HONG KONG) LIMITED (HK) | 2012-02-16 | — | — | US | disclosed |
| EP-2408454-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2012-01-25 | — | — | EP | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
| WO-2010106436-A2 | NOVEL ANTI-INFLAMMATORY AGENTS | RESVERLOGIX CORP. (CA) | 2010-09-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (6 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-11407719-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | MAPKAPK2 780/4885TNKS 1152/4885PARP1 1156/4885 |
| US-20160137613-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | MAPKAPK2 844/4885TNKS 1051/4885PARP1 1176/4885 |
| US-10882828-B2 | Anti-inflammatory agents | VCAM1, ICAM1, IL6 | MAPKAPK2 780/4885TNKS 1152/4885PARP1 1156/4885 |
| US-20210070716-A1 | ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | MAPKAPK2 780/4885TNKS 1152/4885PARP1 1156/4885 |
| US-20190119222-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | MAPKAPK2 844/4885TNKS 1051/4885PARP1 1176/4885 |
| US-20120040954-A1 | NOVEL ANTI-INFLAMMATORY AGENTS | VCAM1, ICAM1, IL6 | MAPKAPK2 844/4885TNKS 1051/4885PARP1 1176/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.